DK0825858T3 - Flerumættede omega-3-fedtsyrer til behandling af inflammatorisk tarmsygdom i kapsler med tidsafhængig frigivelse - Google Patents

Flerumættede omega-3-fedtsyrer til behandling af inflammatorisk tarmsygdom i kapsler med tidsafhængig frigivelse

Info

Publication number
DK0825858T3
DK0825858T3 DK96916052T DK96916052T DK0825858T3 DK 0825858 T3 DK0825858 T3 DK 0825858T3 DK 96916052 T DK96916052 T DK 96916052T DK 96916052 T DK96916052 T DK 96916052T DK 0825858 T3 DK0825858 T3 DK 0825858T3
Authority
DK
Denmark
Prior art keywords
inflammatory bowel
bowel disease
capsules
treatment
fatty acids
Prior art date
Application number
DK96916052T
Other languages
Danish (da)
English (en)
Inventor
Thomas Buser
Emilio Paolo Camporesi
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Application granted granted Critical
Publication of DK0825858T3 publication Critical patent/DK0825858T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96916052T 1995-05-15 1996-05-13 Flerumættede omega-3-fedtsyrer til behandling af inflammatorisk tarmsygdom i kapsler med tidsafhængig frigivelse DK0825858T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9509764.8A GB9509764D0 (en) 1995-05-15 1995-05-15 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
PCT/EP1996/002038 WO1996036329A1 (en) 1995-05-15 1996-05-13 Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids

Publications (1)

Publication Number Publication Date
DK0825858T3 true DK0825858T3 (da) 2005-08-15

Family

ID=10774461

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96916052T DK0825858T3 (da) 1995-05-15 1996-05-13 Flerumættede omega-3-fedtsyrer til behandling af inflammatorisk tarmsygdom i kapsler med tidsafhængig frigivelse

Country Status (23)

Country Link
US (2) US5792795A (cs)
EP (1) EP0825858B1 (cs)
JP (1) JPH11509523A (cs)
KR (1) KR100427112B1 (cs)
CN (1) CN1104237C (cs)
AT (1) ATE294575T1 (cs)
AU (1) AU702692B2 (cs)
BR (1) BR9608785A (cs)
CA (1) CA2221356C (cs)
CZ (1) CZ288560B6 (cs)
DE (1) DE69634693T2 (cs)
DK (1) DK0825858T3 (cs)
ES (1) ES2240995T3 (cs)
GB (1) GB9509764D0 (cs)
HU (1) HU227282B1 (cs)
IL (1) IL118240A (cs)
NO (1) NO320780B1 (cs)
PL (1) PL184085B1 (cs)
PT (1) PT825858E (cs)
SK (1) SK282062B6 (cs)
TW (1) TW397683B (cs)
WO (1) WO1996036329A1 (cs)
ZA (1) ZA963854B (cs)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
KR100569319B1 (ko) * 1997-10-30 2006-04-07 모리시타 진탄 가부시키가이샤 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
ES2201673T3 (es) * 1998-02-11 2004-03-16 Rtp Pharma Corporation Combinacion de esteroides y acidos grasos poiinsaturados para el tratamiento de estados inflamatorios.
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
DE19930030B4 (de) * 1999-06-30 2004-02-19 Meduna Arzneimittel Gmbh CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US20040091545A1 (en) * 2000-12-06 2004-05-13 Justin Slagel Solid polyunsaturated fatty acid compositions
US6548646B1 (en) * 2001-08-23 2003-04-15 Bio-Rad Laboratories, Inc. Reference control for high-sensitivity C-reactive protein testing
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
SE0202188D0 (sv) * 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
EP2295529B2 (en) * 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
AU2002951913A0 (en) * 2002-10-08 2002-10-24 Chevis Agriservices & Consulting Pty. Limited Method of treatment
US20050152969A1 (en) * 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
UA86605C2 (ru) 2004-01-12 2009-05-12 Аплайд Молекьюлер Иволюшн, Инк. Антитело, которое содержит вариант исходного человеческого fс-участка
AU2004314731B2 (en) 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0413729D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
GB0413730D0 (en) * 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US8758814B2 (en) 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
WO2009009040A2 (en) * 2007-07-06 2009-01-15 Baum Seth J Fatty acid compositions and methods of use
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
DK2334295T3 (en) 2008-09-02 2017-10-09 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
US20100130608A1 (en) * 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
JP6176894B2 (ja) 2009-03-09 2017-08-09 プロノヴァ・バイオファーマ・ノルゲ・アーエス 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
US9901551B2 (en) * 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
WO2010127103A1 (en) 2009-04-29 2010-11-04 Amarin Pharma, Inc. Stable pharmaceutical composition and methods of using same
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
KR101798670B1 (ko) 2009-09-23 2017-11-16 아마린 코포레이션 피엘씨 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
CA2781525C (en) * 2009-10-23 2020-05-12 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
CN104220875A (zh) 2010-10-19 2014-12-17 埃尔舍利克斯治疗公司 基于化学感应受体配体的治疗
NZ727980A (en) 2010-11-29 2018-08-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US8551551B2 (en) 2012-01-06 2013-10-08 Perlman Consulting, Llc Stabilization of omega-3 fatty acids in saturated fat microparticles having low linoleic acid content
EP3348262A1 (en) 2012-01-06 2018-07-18 Omthera Pharmaceuticals Inc. Methods for making dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
JP6173437B2 (ja) 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
RS61557B1 (sr) 2012-06-29 2021-04-29 Amarin Pharmaceuticals Ie Ltd Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
EP2745709A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Nutritional compositions with reduced beta-casein a1 and related methods
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3215149A4 (en) 2014-11-06 2018-06-27 Northwestern University Inhibition of cancer cell motility
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
FR3061019B1 (fr) * 2016-12-26 2019-05-24 Belles Feuilles Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments.
FR3061151B1 (fr) * 2016-12-26 2019-05-24 Belles Feuilles Procede et systeme pour conditionner un compose lipidique en doses, capsules de compose lipidique ainsi obtenues et applications de ces capsules.
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2020068163A1 (en) 2018-09-24 2020-04-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
KR200490037Y1 (ko) 2019-04-17 2019-09-11 트랜드 주식회사 원터치 작동방식 욕실 청소용 물분사 헤드
US20220312816A1 (en) * 2019-05-23 2022-10-06 Evonik Operations Gmbh Preparation for use in enhancing formation of short-chain fatty acids (scfas)
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8505569D0 (sv) * 1985-11-25 1985-11-25 Aco Laekemedel Ab Enteralt preparat
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
EP0289204B1 (en) * 1987-04-27 1991-07-17 Efamol Holdings Plc Lithium salt-containing pharmaceutical compositions
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
ATE173616T1 (de) * 1992-11-30 1998-12-15 Pfizer Verabreichungsvorrichtungen mit gestützten flüssigen membranen
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids

Also Published As

Publication number Publication date
KR19990014767A (ko) 1999-02-25
TW397683B (en) 2000-07-11
CZ288560B6 (cs) 2001-07-11
KR100427112B1 (ko) 2004-09-16
CN1104237C (zh) 2003-04-02
ZA963854B (en) 1997-11-17
PT825858E (pt) 2005-08-31
NO975218D0 (no) 1997-11-13
ATE294575T1 (de) 2005-05-15
SK282062B6 (sk) 2001-10-08
DE69634693D1 (de) 2005-06-09
CZ360797A3 (cs) 1998-06-17
GB9509764D0 (en) 1995-07-05
WO1996036329A1 (en) 1996-11-21
EP0825858A1 (en) 1998-03-04
PL323362A1 (en) 1998-03-30
ES2240995T3 (es) 2005-10-16
CN1184421A (zh) 1998-06-10
US5948818A (en) 1999-09-07
CA2221356A1 (en) 1996-11-21
HUP9900337A2 (hu) 1999-06-28
NO975218L (no) 1997-11-13
IL118240A0 (en) 1996-09-12
MX9708758A (es) 1998-03-31
EP0825858B1 (en) 2005-05-04
AU5895596A (en) 1996-11-29
CA2221356C (en) 2003-12-30
SK152397A3 (en) 1998-05-06
HU227282B1 (en) 2011-01-28
PL184085B1 (pl) 2002-08-30
JPH11509523A (ja) 1999-08-24
AU702692B2 (en) 1999-03-04
NO320780B1 (no) 2006-01-30
HUP9900337A3 (en) 2001-12-28
US5792795A (en) 1998-08-11
BR9608785A (pt) 1999-07-06
IL118240A (en) 2001-01-28
DE69634693T2 (de) 2006-05-04

Similar Documents

Publication Publication Date Title
DK0825858T3 (da) Flerumættede omega-3-fedtsyrer til behandling af inflammatorisk tarmsygdom i kapsler med tidsafhængig frigivelse
ATE202473T1 (de) Rasch freisetzende tablettenkerne mit unlöslichen arzneistoffen und mit einem retardüberzug
CA2065809A1 (en) Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids
FI823975L (fi) Farmaceutisk flerenhetssammansaettning
FI933680A0 (fi) Orala doseringsformer foerdroejd frigoering foer behandling av tarmstoerningar
CA2065652A1 (en) Controlled release gastroresistant pharmaceutical formulations for oral administration containing bile acids and their salts
KR920703046A (ko) 경구용 항응고제/혈소판 억제제 저용량 제형
PL327323A1 (en) Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases
JPS5350316A (en) Drug composition for oral administration
KR940008688A (ko) 필수지방산에 의해 킬레이트화된 아연정제